943974-70-7

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 262444-48-4 4-chloro-7-(1,4-dioxaspiro[4.5]decan-8-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 123148-78-7 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1500-85-2 7-deazaadenine 
• 163622-50-2 4-amino-5-iodo-7H-pyrrolo[2,3‐d]pyrimidine 
• 1272667-14-7 5-iodo-7-(1,4-dioxaspiro[4.5]decan-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 

Downstream Products

• 262444-50-8 4-(4-amino-5-(4-amino-3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanone 
• 862728-36-7 trans-{4-[4-(4-amino-5-iodo-pyrazolo[2,3-d]pyrimidin-7-yl)-cyclohexyl]}-1-methyl-piperazin-2-one 

Relevant academic research and scientific papers

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA

Provided herein are compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.

Alkynyl (hetero) aromatic ring compound for inhibiting activity of protein tyrosine kinase

The present invention relates to an alkynyl (hetero) aromatic ring compound having protein tyrosine kinase inhibition effect, and a preparation method thereof, a pharmaceutical composition containingthe alkynyl (hetero) aromatic ring compound, and uses of

BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS

The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease.